The approval was based on data from the phase 3 heiGHt trial, which compared Skytrofa to somatropin in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. Skytrofa ® ...

The approval was based on data from the phase 3 heiGHt trial that assessed Skytrofa in 161 treatment-naïve, prepubertal patients with growth hormone deficiency. The Food and Drug Administration has ...

Ascendis Pharma announced that the US Food and Drug Administration (FDA) has approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11 ...

SKYTROFA ® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency. [1] SINGAPORE, May 29, 2025 /PRNewswire/ -- ...